NCT05918185Completed
Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma
The Role of the Comprehensive Geriatric Assessment in Elderly Patients With Multiple Myeloma: A Single Center Prospective Study
Source: ClinicalTrials.gov · Last updated 3 Feb 2026
Brief summary (registry, in English)
This study evaluates the association between a comprehensive geriatric assessment and laboratory biomarkers with the side effects of chemotherapy in older patients with multiple myeloma (MM). The comprehensive geriatric assessment is a tool that can help to determine how fit a patient is. It is composed of a series of questions and tests designed for older people to evaluate their physical function, mental status, mental health, nutritional status, social support, level of social activity, and the presence of other medical problems. In addition to geriatric assessment domains, laboratory biomarkers may provide information on physiologic dysfunction as a measure for evaluation of frailty in the cancer setting. This study will help researchers in the future by predicting which patients will have more side effects with chemotherapy based on their comprehensive geriatric assessment and laboratory biomarkers, which will allow adjustments to treatment in older adult patients with MM.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 56 (actual)
- First submitted
- 17 May 2023
- Start date
- 15 Feb 2023
- Primary completion date
- 30 Aug 2025
- Lead sponsor
- Mayo Clinic
- Diseases
- Multiple myeloma
- NCT number
- NCT05918185
What you commit to
- Study type: Observational
- Participants enrolled: 56
- From 15 Feb 2023 to the primary completion date, 30 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received > 1 prior line of treatment
Other illness
- Severe mental or cognitive disorder precluding geriatric assessment
Other
- Patients included in an interventional therapeutic trial
- Not able to give informed consent
Who the study is looking for
- Age >= 65 years
- Diagnosis of MM based on International Myeloma Working Group (IMWG) diagnostic criteria
- Newly diagnosed or have received 1 prior line of treatment
- Planned to start a new treatment for MM within 30 days
- Transplant eligible or ineligible
- Fluent in English (all assessment tools are in English)
- Able to provide written informed consent
Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
Related publications
- Self-reported geriatric impairments and treatment toxicity in older patients with multiple myeloma.Blood Adv · 2026 · PMID 42508993
This page is information, not medical advice. Discuss any trial with your doctor.